Maki Kiso

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2”.

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

Nature(2022)10.1038/s41586-022-04856-1

N/A

10.7DataRank · unranked

293 citations

Maki Kiso, Shun Iida, Masaki Imai, Emi Takashita, Makoto Kuroda +64 more

The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters

Research Square(2021)10.21203/rs.3.rs-1211792/v1

N/A

8.4DataRank · unranked

87 citations

Peter Halfmann, Tadashi Maemura, Kiyoko Iwatsuki‐Horimoto, Shun Iida, Maki Kiso +60 more

Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction

Frontiers in Cell and Developmental Biology(2020)10.3389/fcell.2020.00856

N/A

0.466DataRank · unranked

6 citations

Maki Kiso, Peter Halfmann, Pamela R. Westmark, Yoshihiro Kawaoka, Cara J. Westmark

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Nature(2022)10.1038/s41586-022-04441-6

N/A

0DataRank · unranked

699 citations

Shun Iida, Kiyoko Iwatsuki‐Horimoto, Tadashi Maemura, Maki Kiso, Suzanne M. Scheaffer +77 more

Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents

Nature(2022)10.1038/s41586-022-05482-7

N/A

0DataRank · unranked

110 citations

Peter Halfmann, Shun Iida, Seiya Yamayoshi, Yuri Furusawa, Maki Kiso +21 more

Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters

Nature Microbiology(2022)10.1038/s41564-022-01170-4

N/A

0DataRank · unranked

39 citations

Maki Kiso, Masaki Imai, Seiya Yamayoshi, Mutsumi Ito, Seiichiro Fujisaki +10 more

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.08.26.505450

N/A

0DataRank · unranked

8 citations

Shun Iida, Peter Halfmann, Seiya Yamayoshi, Yuichiro Hirata, Kiyoko Iwatsuki‐Horimoto +25 more

Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

Nature Communications(2023)10.1038/s41467-023-36729-0

N/A

0DataRank · unranked

45 citations

Kohei Tsuji, Hironori Hayashi, Haydar Bulut, Maki Kiso, Masaki Imai +30 more

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate

The Lancet Regional Health - Western Pacific(2023)10.1016/j.lanwpc.2023.100777

N/A

0DataRank · unranked

2 citations

Mutsumi Ito, Maki Kiso, Seiya Yamayoshi, Kiyoko Iwatsuki‐Horimoto, Yuko Sakai‐Tagawa +15 more

An orally available P1′-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier

PNAS Nexus(2024)10.1093/pnasnexus/pgae578

N/A

0DataRank · unranked

9 citations

Haydar Bulut, Hironori Hayashi, Kohei Tsuji, Hiromi Ogata-Aoki, Maki Kiso +23 more

Characterization of a new SARS-CoV-2 variant that emerged in Brazil

Proceedings of the National Academy of Sciences(2021)10.1073/pnas.2106535118

N/A

0DataRank · unranked

87 citations

Peter Halfmann, Seiya Yamayoshi, Kiyoko Iwatsuki‐Horimoto, S. Chiba, Tokiko Watanabe +54 more

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters

Journal of Virology(2021)10.1128/jvi.01551-21

N/A

0DataRank · unranked

26 citations

Masaki Imai, Kenji Maeda, Noriko Nakajima, Nobuyo Higashi‐Kuwata, Kiyoko Iwatsuki‐Horimoto +9 more